Medical Doctor Program year 2020 Reported 2019–2020 Source: CMS Open Payments, 2026 publication

James Morris

Pain Medicine Eugene, OR Medical Doctor

NPI 1902904501 CMS profile 86770

2401 River Rd, Suite 101, Eugene, OR 97404

Open in the dashboard

General payments

$866

53 records reported · program years 2019–2020

Research payments

$0

Paid to them · None reported · program years 2019–2020

Ownership & investment interest

$0

None reported

Through program year 2020, James Morris of Eugene, OR is reported in the CMS Open Payments database as having received $866 across 53 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 32nd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

2 rows
Year Kind Relative to this record's peak year Amount Records
2020 General $36 2
2019 General $830 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • James Morris
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to James Morris were reported at $0. Among 757 Pain Medicine profiles paid that year, the median was $470 and the middle half received between $146 and $1,462.

Show as a table
Year James Morris Pain Medicine median Middle half National median
2019 $830 $506 $144–$1,566 $163
2020 $36 $315 $96–$934 $114
2021 $0 $452 $134–$1,237 $132
2022 $0 $475 $124–$1,407 $149
2023 $0 $480 $136–$1,384 $160
2024 $0 $521 $164–$1,511 $164
2025 $0 $470 $146–$1,462 $169

Breakdown

Who paid General payments · program years 2019–2020
  1. Amgen Inc. $304 15 payments
  2. Teva Pharmaceuticals USA, Inc. $151 12 payments
  3. Scilex Pharmaceuticals Inc. $70 4 payments
  4. Lilly USA, LLC $59 3 payments
  5. Novartis Pharmaceuticals Corporation $52 3 payments
  6. Pfizer Inc. $40 3 payments
  7. Flexion Therapeutics, Inc. $34 2 payments
  8. Collegium Pharmaceutical, Inc. $26 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $25 2 payments
  10. Allergan Inc. $24 2 payments
  11. Other $81 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2020
  1. Food and Beverage $866 53 payments
Products named General payments · program years 2019–2020
  1. AIMOVIG $357 18 payments
  2. Ajovy $151 12 payments
  3. ZTLido 30 POUCH in 1 CARTON 1 PATCH in 1 POUCH $70 4 payments
  4. EMGALITY $59 3 payments
  5. EMBEDA $40 3 payments
  6. LYRICA $40 3 payments
  7. Zilretta $34 2 payments
  8. XTAMPZA $26 2 payments
  9. Amitiza $25 2 payments
  10. BOTOX $24 2 payments
  11. Other $131 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

13

Median for Pain Management: 951

Drug cost

$108

Median for Pain Management: $26,034

Branded share of claims

0%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 13 $108

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Records

53 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2020

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record